Replies to post #298368 on Avid Bioservices Inc (CDMO)

[biopharm]

Nice...non disclosures in pipelines grow yet again
http://www.tesarobio.com/en/pipeline

Every one of them a strong contender for collaborators with Peregrine

[TSmith4659]

Tesoro's corporate goals for Immuno-oncology platform:

Continue to enroll patients with MSI-H metastatic endometrial cancer in the ongoing trial of TSR- 042, with the intent of submitting the results and a request to FDA for accelerated approval
Identify the first clinical candidate within the MD Anderson collaboration in 2Q 2017
Identify dose and schedule for TSR-022 by mid-2017 and for TSR-022 plus an anti-PD-1 mAb in 2H

Don't like adding to the conspiracies, but.....



TS